ClinVar Miner

Submissions for variant NM_000249.4(MLH1):c.2110G>A (p.Val704Met)

dbSNP: rs587781811
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001229217 SCV001401655 uncertain significance Hereditary nonpolyposis colorectal neoplasms 2025-01-19 criteria provided, single submitter clinical testing This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 704 of the MLH1 protein (p.Val704Met). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with MLH1-related conditions. ClinVar contains an entry for this variant (Variation ID: 956419). Invitae Evidence Modeling incorporating data from in vitro experimental studies (internal data) indicates that this missense variant is not expected to disrupt MLH1 function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Genetic Services Laboratory, University of Chicago RCV001819928 SCV002068043 uncertain significance not specified 2020-04-20 criteria provided, single submitter clinical testing DNA sequence analysis of the MLH1 gene demonstrated a sequence change, c.2110G>A, in exon 19 that results in an amino acid change, p.Val704Met. This sequence change has not been described in population databases (gnomAD, ExAC). While this sequence change has not been reported in patients with MLH1-related disorders, a different amino acid change at the same location, p.Val704Leu, has been described in a suspected Lynch syndrome patient (PMID: 31386297). The p.Val704Met change affects a poorly conserved amino acid residue located in a domain of the MLH1 protein that is not known to be functional. The p.Val704Met substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to these contrasting evidences and the lack of functional studies, the clinical significance of the p.Val704Met change remains unknown at this time.
Ambry Genetics RCV002418789 SCV002725238 uncertain significance Hereditary cancer-predisposing syndrome 2024-04-07 criteria provided, single submitter clinical testing The p.V704M variant (also known as c.2110G>A), located in coding exon 19 of the MLH1 gene, results from a G to A substitution at nucleotide position 2110. The valine at codon 704 is replaced by methionine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species, and methionine is the reference amino acid in other vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Baylor Genetics RCV003469402 SCV004192968 uncertain significance Colorectal cancer, hereditary nonpolyposis, type 2 2023-07-15 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV002418789 SCV004359273 uncertain significance Hereditary cancer-predisposing syndrome 2022-11-21 criteria provided, single submitter clinical testing This missense variant replaces valine with methionine at codon 704 of the MLH1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with MLH1-related disorders in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.